Welcome to our dedicated page for Prothena news (Ticker: PRTA), a resource for investors and traders seeking the latest updates and insights on Prothena stock.
Prothena Corporation plc (NASDAQ: PRTA) is described in its own press releases as a late-stage clinical biotechnology company focused on protein dysregulation in neurodegenerative and rare peripheral amyloid diseases. The PRTA news feed on Stock Titan aggregates these company communications, giving investors and observers a single place to follow Prothena’s disclosures and milestones.
In its recent news, Prothena has highlighted progress across a pipeline that includes both wholly-owned and partnered programs. Updates have covered clinical development for Parkinson’s disease through the prasinezumab collaboration with Roche, ATTR amyloidosis with cardiomyopathy via coramitug (formerly PRX004) now being developed by Novo Nordisk, and Alzheimer’s disease programs such as BMS-986446 (formerly PRX005) with Bristol Myers Squibb, PRX012, and the dual Aβ/tau vaccine PRX123. The company has also issued releases on its CYTOPE technology platform, workforce restructuring, and financial results.
Readers of the PRTA news page can review press releases on topics such as Phase 2 and Phase 3 trial plans, Fast Track designations, preclinical data from the TDP-43 CYTOPE program, and corporate actions including an Extraordinary General Meeting to approve a capital reduction to create distributable reserves. Governance and leadership updates, such as changes to the Board of Directors, are also disclosed through these announcements.
By following this curated stream of Prothena’s own news, users can see how the company presents the status of its investigational therapeutics, collaborations with partners like Roche, Novo Nordisk and Bristol Myers Squibb, and its capital and cost structure decisions. The PRTA news page is intended as a convenient starting point for reviewing Prothena’s publicly released information over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Prothena Corporation plc (NASDAQ:PRTA), a clinical biotechnology firm, announced its participation in a fireside chat at the 2023 Bank of America Healthcare Conference in Las Vegas on May 9, 2023, at 9:20 AM PT. This event will showcase insights from the company’s senior management regarding their investigational therapeutics pipeline, focusing on protein dysregulation and neurodegenerative diseases. A live webcast of the chat will be available on Prothena's investor relations website, with a replay accessible for 90 days afterward. Prothena specializes in developing treatments for conditions like AL amyloidosis, ATTR amyloidosis, Alzheimer’s, and Parkinson’s diseases, positioning itself as a key player in addressing these pressing health challenges.
Walgreens and Prothena have announced a collaboration to enhance patient recruitment for Prothena's PRX012, a potential Alzheimer’s treatment currently in the ASCENT-2 clinical trial. Walgreens will utilize its extensive network and healthcare capabilities to identify suitable candidates, focusing on underserved communities. This trial has received Fast Track designation from the FDA, indicating its potential significance in addressing Alzheimer’s disease, which affects over 6.5 million Americans aged 65 and older. The partnership aims to create a more diverse patient population for the trial, aligning with the ENACT Act to improve inclusivity in Alzheimer’s research. Key topline data from ongoing Phase 1 studies is expected by the end of 2023.
Prothena Corporation plc (NASDAQ:PRTA) unveiled new preclinical data for its anti-amyloid beta product candidate, PRX012, at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases in Gothenburg, Sweden. The data indicates that PRX012 exhibits a 20-fold greater affinity for amyloid beta protofibrils compared to lecanemab and clears pyroglutamate-modified amyloid beta at lower concentrations than donanemab. These findings support PRX012's potential as a best-in-class treatment for Alzheimer’s disease, with implications for improved patient access and administration.
Prothena Corporation plc (NASDAQ: PRTA) will participate in a fireside chat at the Stifel 2023 Virtual CNS Days on Tuesday, March 28, 2023, at 10:30 AM ET. The event will be accessible via a live webcast through the company's investor relations section at www.prothena.com. After the live presentation, a replay of the webcast will be available for at least 90 days.
Prothena specializes in investigating therapeutics for neurodegenerative diseases and has a diverse pipeline targeting conditions like AL amyloidosis, ATTR amyloidosis, Alzheimer’s, and Parkinson’s diseases.
Prothena Corporation (NASDAQ:PRTA) showcased its leadership in Alzheimer's and Parkinson's disease treatments at the 2023 International Conference on Alzheimer's and Parkinson's Diseases held in Gothenburg, Sweden. The highlight was an oral presentation on PRX012, a next-generation anti-amyloid beta antibody, showing a 20-fold higher affinity for amyloid beta protofibrils and enhanced plaque clearance compared to existing treatments. Prothena also hosted a symposium on disease-modifying treatments and participated in panel discussions. Collaborating partner Roche presented findings on prasinezumab for Parkinson's disease.